In a Phase 2 study of first‐line sorafenib in patients with advanced HCC, those with CP B (n = 38 [28%]) fared worse than those with CP A, with 12.9 weeks therapy duration, 13 weeks median progression‐free survival (PFS), 14 weeks OS, and encephalopathy and worsening ascites in 11% and 18% of patients, respectively.42, 43. This evidence concerns the gene CP and Encephalopathy.